Hemodez-N - instructions for use, doses, side effects, contraindications

Polyvinylpyrrolidone low molecular weight medical 8000 ± 2000 (in terms of anhydrous) - 60.00 g, sodium chloride - 5.50 g, potassium chloride - 0.42 g, calcium chloride 6-water - 0.50 g, magnesium chloride 6-aqueous - 0,005 g, sodium bicarbonate 0.23 g, water for injection - up to 1 l.

Description:Transparent liquid from light yellow to yellow.

Pharmacotherapeutic group:Detoxifying agent

ATX: & nbsp

B.05.A.A Blood plasma preparations and plasma-substituting drugs

Pharmacodynamics:

The action of Hemodeza-H is due to the ability of low molecular weight polyvinylpyrrolidone to bind toxins circulating in the blood and quickly remove them from the body. Hemodez-H differs from Hemodesa by a lower molecular weight of polyvinylpyrrolidone. The decrease in the molecular weight of the polymer accelerates the excretion of it by the kidneys from the body and improves the detoxification properties of the preparation. It increases renal blood flow, increases glomerular filtration and increases diuresis.

Pharmacokinetics:

Metabolic transformations in the body are not exposed. Quickly excreted by the kidneys, within 4 hours 80% is output, and after 12 - 24 hours - completely.

Indications:

Shock (posttraumatic, postoperative, burn, hemorrhagic), intoxication (toxic diseases of the gastrointestinal tract: dysentery, dyspepsia, salmonellosis, as a means of detoxification in the postoperative period in peritonitis, liver disease,accompanied by the development of liver failure; intestinal obstruction; thyrotoxicosis; burn disease; acute radiation sickness; sepsis; pneumonia; acute phase of myocardial infarction; hemolytic disease of newborns; intrauterine infection and toxemia newborns; Toxicosis of pregnant women.

Contraindications:

Increased sensitivity to the drug, intracranial hypertension, hemorrhagic stroke, post-traumatic brain injury, cardio - vascular insufficiency IIb - III degree, respiratory insufficiency, severe allergic reactions, thromboembolism, oliguria, anuria, acute nephritis, asthma, phlebothrombosis.

Carefully:Not described.

Pregnancy and lactation:Not described.

Dosing and Administration:

Intravenously drip (40 - 80 cap / min), through a device with a filter.

The dose depends on the age of the patient and the severity of intoxication.

Single dose for adults - 200-500 ml; for children - 5-10 ml / kg; the maximum single dose for infants is 50-70 ml, 2-5 years - 100 ml, 5-10 years -150 ml, 10-15 years - 200 ml. The drug is administered once or repeatedly (up to 2 times a day) for 1-10 days, depending on the severity of intoxication.In acute gastrointestinal infections, burn and radiation diseases are administered 1-2 times a day; with hemolytic disease and toxemia of newborns - 2-8 times a day (daily or every other day); with large focal myocardial infarction (in the 1st day) - 200 ml once, with complications for 2 days - 200 ml.

Side effects:

With the slow introduction of Haemodesum-H, complications do not usually arise. Introduction with increased speed can cause a decrease in blood pressure, tachycardia, difficulty breathing and require the introduction of vasoconstrictor and cardiac agents, calcium chloride. Individual patients may experience allergic reactions, up to the development of anaphylactic shock. In these cases, you should immediately stop the infusion, conduct symptomatic therapy (introduce antihistamines, cardiotonic drugs, glucocorticoids, vasopressive drugs).

Overdose:

In case of an overdose, the drug should be withdrawn and symptomatic therapy should be performed.

Interaction:Not described.

Special instructions:

With extensive burns combined with the introduction of plasma, albumin, gamma globulin.

Before starting the infusion, the doctor must check the integrity and integrity of the package.The drug should be clear, free of sediment, sediment and mold. The results of visual inspection are recorded in the medical history.

Before administration, the solution is warmed to body temperature.

Effect on the ability to drive transp. cf. and fur:Not described.

Form release / dosage:

Solution for infusions of 200, 400 ml.

Packaging:In the glass bottles for blood, infusion and transfusion preparations with a capacity of 250 or 450 ml, corked with rubber stoppers and crimped with aluminum caps. Each bottle, along with instructions for medical use, is placed in a pack of cardboard boxes. 15 packs of bottles with a capacity of 450 ml or 28 packets with bottles with a capacity of 250 ml are placed in a box of cardboard box with cardboard padding or in a box of corrugated cardboard with gaskets and grids ("nests").

For hospitals: 15 or 28 bottles with a capacity of 250 ml or 15 bottles with a capacity of 450 ml, together with instructions for medical use in quantities corresponding to the number of primary packages, placed in a box of cardboard boxed with a cardboard liner or in a box of cardboard corrugated with gaskets and gratings "nests").

Storage conditions:Store at temperatures between 5 ° and 25 ° C in places inaccessible to children. Non-wetting of the inner surface of bottles is not a contraindication to the use of the drug.

Shelf life:

2 years. Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LSR-002137/08

Date of registration:27.03.2008 / 11.09.2012

Expiration Date:Unlimited

The owner of the registration certificate:MOSFARM, LLCMOSFARM, LLC

Manufacturer: & nbsp

MOSFARM, LLC

Information update date: & nbsp21.03.2017

Illustrated instructions

Instructions

Hemodez-H (Haemodes-N)